Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

836
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
836
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

209
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
209
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

915
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
915
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

3.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.8K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

758
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
758

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Detecting Occlusion Myocardial Infarction with an AI-Powered ECG Model: A Retrospective Cohort Study.

Journal of personalized medicine·2026
Same author

Heart Failure and Cognitive Impairment Through the Lens of the Gut Microbiome: A Narrative Review.

Journal of personalized medicine·2025
Same author

Vitamin D and Cardiovascular Disease: The "Good", the "Bad", and the "Unknown".

Reviews in cardiovascular medicine·2025
Same author

Colorectal cancer in heart transplant recipients: A competing risk analysis.

European journal of clinical investigation·2025
Same author

The Role of Cystatin C in the Prediction of Contrast-Induced Acute Kidney Injury Following Coronary Procedures: A Systematic Review.

Reviews in cardiovascular medicine·2025
Same author

One-Year Prognostic Differences and Management Strategies between ST-Elevation and Non-ST-Elevation Myocardial Infarction: Insights from the PRAISE Registry.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2025

Related Experiment Video

Updated: Jan 13, 2026

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.0K

GLP-1 Receptor Agonists in Heart Failure.

Ali Reza Rahmani1, Simrat Kaur Dhaliwal1, Paola Pastena2

  • 1Division of Cardiology, Department of Medicine, Stony Brook University, Stony Brook, NY 11790, USA.

Biomolecules
|October 29, 2025
PubMed
Summary

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) show promise for heart failure (HF) treatment. These agents improve symptoms and reduce weight in HF patients by targeting key biological pathways involved in HF.

Keywords:
GLP-1 RAsheart failuremolecular pathwayspathophysiology

More Related Videos

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.7K
Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

11.7K

Related Experiment Videos

Last Updated: Jan 13, 2026

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.0K
Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.7K
Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

11.7K

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Heart failure (HF) presents a significant public health challenge, exacerbated by rising rates of obesity and diabetes.
  • Despite advancements, HF remains linked to substantial morbidity and mortality.
  • Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially for type 2 diabetes, exhibit cardiovascular benefits.

Purpose of the Study:

  • To explore the mechanistic overlap between GLP-1 receptor signaling and heart failure pathophysiology.
  • To evaluate the potential of GLP-1 RAs as adjunctive therapies for heart failure, particularly in metabolically driven forms.

Main Methods:

  • Review of recent clinical trials (e.g., STEP-HFpEF, SUMMIT) demonstrating GLP-1 RA efficacy in HFpEF.
  • Analysis of biological pathways influenced by GLP-1 RAs relevant to HF.
  • Examination of GLP-1 RA effects on sympathetic activity, inflammation, oxidative stress, and cardiac metabolism.

Main Results:

  • GLP-1 RAs have shown improvements in HFpEF symptoms and significant weight loss.
  • These agents modulate pathways including sympathetic nervous system activity, inflammatory cytokine signaling, and oxidative stress.
  • GLP-1 RAs impact vascular function, endothelial health, and renal sodium handling, improving hemodynamics.

Conclusions:

  • GLP-1 RAs demonstrate a mechanistic link to HF pathophysiology through systemic metabolic and anti-inflammatory actions.
  • Observed clinical benefits in HF patients are supported by these multifaceted biological effects.
  • GLP-1 RAs represent a potential adjunctive treatment strategy for specific HF phenotypes, warranting further investigation into direct cardiac effects.